Skip Navigation

European Heart Journal 1992 13(8):1092-1100;
Copyright © 1992 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by SILKE, B.
Right arrow Articles by SALMINEN, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SILKE, B.
Right arrow Articles by SALMINEN, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1992 The European Society of Cardiology

A double-blind, parallel-group comparison of flosequinan and enalapril in the treatment of chronic heart failure

B. SILKE, H. TENNET*, J. FISCHER-HANSEN{dagger}, N. KELLER{dagger}, J. HEIKKILA{dagger} and K. SALMINEN{dagger}

Department of Therapeutics and Pharmacology, Queen's University of Belfast Northern Ireland
*Leeds General Infirmary Leeds, U.K.
{dagger}Department of Cardiology, Hvidovre Hospital Copenhagen, Denmark
{ddagger}Cardiovascular Laboratory, University Central Hospital Helsinki, Finland

Received 23 July 1991; revised 2 December 1991; .

Correspondence. Dr B. Silke, Dept of Therapeutics and Pharmacology, Queen's University of Belfast, Whitla Medical Building, 97 Lisburn Road, Belfast, BT7 9BL. Northern Ireland.

Abstract

The effects of flosequinan and enalapril on exercise capacity (bicycle exercise duration), quality-of-life symptomatology (visual analogue scales) and New York Heart Association (NYHA) grading, were compared in 61 patients with chronic heart failure (N YHA, grade III).

Bicycle exercise duration improved similarly with flosequinan ( + 27%) and enalapril ( +18%); in patients completing the study, flosequinan produced a significantly greater increase in exercise time at week 12, compared with enalapril (P = 0.02). Improvements in visual analogue scores relating to general health, energy and vitality, ability to perform physical activities and breathing performance, were equivalent for both drugs. Changes in N YHA classification showed that 27 (55% ) of 49 patients completing the study had improved by at least one N YHA grade (15 (68%) patients on flosequinan; 12 (44%) on enalapril).

The overall safety and tolerability of the two treatments was similar; 18 patients reported adverse effects while on flosequinan, compared with 19 patients on enalapril. Neither treatment was associated with any clinically important changes in haematological or biochemical variables, although some treatment-related effects were observed.

This study confirms that flosequinan achieved similar efficacy to enalapril in the symptomatic relief of chronic heart failure. The effect of flosequinan on survival in chronic heart failure has not been tested; pending such studies, our data suggest that it may prove a useful alternative therapy in patients where ACE inhibitors are contraindicated or poorly tolerated.

Key Words: Flosequinan • enalapril • vasodilator therapy • severe heart failure


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.